Positive RCT results for CytoSorb in heart transplant show reduced organ failure and shorter ICU stays

Cytosorbents Corp

Vasoplegic syndrome rate 20% vs 48% control (p=0.028); odds 6.4× lower in CytoSorb group.
Acute kidney injury 36.7% vs 76.0% control (p=0.004); no renal replacement therapy needed (0% vs 16%).
Median ICU stay 8.5 days vs 12 days control (p=0.022); mechanical ventilation 25 vs 65 hours.
No removal of anti-rejection drug mycophenolic acid and no device-related adverse events reported.
Study published in European Society of Cardiology journal ESC Heart Failure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.